Expanded Access Program (EAP) | Compassionate Use & Patient Care

Home >> Article >> Expanded Access Program (EAP) | Compassionate Use & Patient Care

Expanded Access Program (EAP) | Compassionate Use & Patient Care

Understanding Compassionate Use and Early Access Programs

Patients with serious, life-threatening, or rare disorders often have limited treatment options. In several cases, approved treatments may be unavailable, ineffective, or inaccessible in their country. In such cases, Expanded Access Programs (EAPs) may establish a pathway for eligible patients to access investigational medicines. These programs are for those who may benefit from treatment before the medicine receives full commercial approval.

Expanded Access Programs are important in global healthcare by helping bridge the gap between clinical development and commercial availability. These programs are widely used in oncology, hematology, neurology, immunology, rare diseases, and other specialty therapeutic areas where patients may urgently need specialty treatments.

Ikris Pharma Network supports patients and clinicians by facilitating access to investigational medicines through compliant patient access pathways worldwide

What is an Expanded Access Program (EAP)?

An Expanded Access Program (EAP) is a regulatory pathway that allows eligible patients with serious or life-threatening medical conditions to access investigational medicines outside of clinical trials when no satisfactory approved treatment options exist.

Expanded Access Programs provide treatment rather than conduct research. They enable physicians to request access to investigational therapies on behalf of patients who need urgent treatment but cannot participate in a clinical study.

EAPs are important for patients with:

Advanced cancers
Rare diseases
Genetic disorders
Neurological conditions
Serious chronic illnesses
Hematologic malignancies

Depending on the country and regulatory framework, these programs known as Compassionate Use Programs, Managed Access Programs, Early Access Programs, or Named Patient Programs (NPP).

Why Expanded Access Programs Matter?

Medical research continues to accelerate, with thousands of investigational medicines being manufactured worldwide. However, there are several patients who cannot wait for lengthy approval processes when already struggling with serious illnesses.

Expanded Access Programs help address this challenge by providing patients with access to therapies before they become commercially available.

For several patients, these programs may represent:

An additional therapeutic option when approved therapies have not worked
Access to specialty medicines before market launch
Continued treatment following clinical trial participation
Access to therapies not yet available in their country

By creating structured pathways for medicine access, EAPs help support patient while maintaining regulatory oversight and safety standards.

Global Demand for Expanded Access Programs:
The need for Expanded Access Programs (EAPs) is very high as precision medicine, targeted therapies, gene therapies, biologics, and rare disease treatments become so important.
Many life-saving medicines receive regulatory approval in very few countries years before becoming available everywhere. During this time-span, patients and physicians often access through Expanded Access Programs.
EAPs are important in:
- Oncology
- Hematology
- Neurology
- Immunology
- Genetic Disorders
- Rare Diseases
- Advanced Cell and Gene Therapies
As healthcare industry embracing personalized medicine, demand for patient access programs (PAPs) is expected to continue increasing worldwide.

Industry Insights and Patient Access Statistics:
According to the World Health Organization (WHO), over 300 million people worldwide are estimated to be living with a rare disease. These numbers highlight the significant unmet medical needs faced by patients worldwide. Many of these patients may need access to specialty therapies through Expanded Access Programs (EAPs), Compassionate Use Programs (CUPs), or other patient access pathways.

These factors highlight the high importance of patient access pathways in modern healthcare.

Who Qualifies for an Expanded Access Program?
Patients who may qualify for this program generally meet one or more of the following criteria:
- Serious or Life-Threatening Condition: The patient has a life-threatening disease requiring urgent medical intervention.
- No Approved Treatment Available: No approved treatment exists for the patient's condition.
- Exhausted Available Treatment Options: Available therapies have been used but have not achieved the desired clinical outcome.
- No Access to Clinical Trials: The patient cannot participate in an active clinical trial because of eligibility restrictions, geographical limitations, or lack of available enrollment.
Eligibility requirements may vary depending on the country, medicine, manufacturer policies, and applicable regulations.

Regulatory Authorities Supporting Expanded Access Programs:

The programs operate under the oversight of regulatory authorities worldwide.

Types of Patient Access Programs (PAPs):

PAPs may be known by different names globally.

Expanded Access Program (EAP): Provides access to investigational medicines before commercial approval.

Compassionate Use Program (CUP): Allows access to investigational therapies for patients with serious or life-threatening conditions.

Early Access Program: Provides treatment access before a medicine becomes commercially available.

Managed Access Program (MAP): Supports controlled medicine access under structured frameworks.

Post-Trial Access Program: Allows patients to continue treatment following participation in a clinical trial.

United States: The FDA Expanded Access Program provides pathways for eligible patients to access investigational medicines outside clinical trials.
Canada: Health Canada operates the Special Access Program (SAP).
European Union: The European Medicines Agency (EMA) supports Compassionate Use Programs across member states.
United Kingdom: The MHRA administers the Early Access to Medicines Scheme (EAMS).
Australia: The Therapeutic Goods Administration (TGA) supports Special Access Schemes.
India: The Central Drugs Standard Control Organization (CDSCO) oversees relevant regulatory pathways that may support patient access to unapproved medicines under the Named Patient Program in India.

Expanded Access Program vs Named Patient Program vs Compassionate Use:

Program Type	Purpose	Typical Patient Access
Expanded Access Program (EAP)	Access to investigational medicines before approval	Individual or multiple patients
Compassionate Use Program (CUP)	Access for serious or life-threatening conditions	Individual or group access
Named Patient Program (NPP)	Access for a specific patient	Single patient
Managed Access Program (MAP)	Structured access under defined frameworks	Multiple patients
Post-Trial Access Program	Continued treatment after trial completion	Former trial participants

While terminology differs across countries, the objective is common: to help eligible patients access important therapies before widespread commercial availability.

03-03-2025

Written By:

Nitin